[go: up one dir, main page]

MX2014004719A - Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal. - Google Patents

Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal.

Info

Publication number
MX2014004719A
MX2014004719A MX2014004719A MX2014004719A MX2014004719A MX 2014004719 A MX2014004719 A MX 2014004719A MX 2014004719 A MX2014004719 A MX 2014004719A MX 2014004719 A MX2014004719 A MX 2014004719A MX 2014004719 A MX2014004719 A MX 2014004719A
Authority
MX
Mexico
Prior art keywords
intestinal
composition
promotion
tolerance
prevention
Prior art date
Application number
MX2014004719A
Other languages
English (en)
Other versions
MX390997B (es
Inventor
Norbert Sprenger
Clara Garcia-Rodenas
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004719(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2014004719A publication Critical patent/MX2014004719A/es
Publication of MX390997B publication Critical patent/MX390997B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se relaciona con una composición que comprende, al menos, un ácido graso poliinsaturado de cadena larga, al menos un probiótico y una mezcla de oligosacáridos, donde dicha mezcla contiene, al menos, un oligosacárido N-acetilado, al menos un oligosacárido sialilado y, al menos, un oligosacárido neutro, para su uso en la promoción de la angiogénesis intestinal y de la absorción de nutrientes y de la tolerancia a la alimentación enteral y/o en la prevención y/o en el tratamiento de la inflamación intestinal, tal como la enterocolitis necrotizante, y/o en la recuperación posterior a un daño o cirugía intestinal. Esta composición se adapta particularmente para su uso en bebés, en particular, bebés prematuros.
MX2014004719A 2011-10-18 2012-10-15 Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal. MX390997B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185606 2011-10-18
PCT/EP2012/070359 WO2013057062A1 (en) 2011-10-18 2012-10-15 Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery

Publications (2)

Publication Number Publication Date
MX2014004719A true MX2014004719A (es) 2015-02-05
MX390997B MX390997B (es) 2025-03-21

Family

ID=47010618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004719A MX390997B (es) 2011-10-18 2012-10-15 Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal.

Country Status (11)

Country Link
US (1) US20140286908A1 (es)
EP (1) EP2768311B2 (es)
CN (1) CN103889239A (es)
AU (1) AU2012324985B2 (es)
BR (1) BR112014008425A2 (es)
CL (1) CL2014000791A1 (es)
ES (1) ES2666491T5 (es)
MX (1) MX390997B (es)
PH (1) PH12014500509B1 (es)
RU (1) RU2624233C2 (es)
WO (1) WO2013057062A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767043C (en) 2009-07-06 2020-07-14 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
MX376863B (es) 2010-12-31 2025-03-07 Abbott Lab Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.
DK2658549T3 (da) 2010-12-31 2020-06-29 Abbott Lab Fremgangsmåder til reduktion af incidensen af oxidativt stress under anvendelse af humane mælkeoligosaccharider, vitamin c og anti-inflammatoriske midler
PH12014500185A1 (en) 2011-07-22 2019-10-11 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
SG2014013478A (en) 2011-08-29 2014-05-29 Abbott Lab Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN103250814B (zh) * 2013-06-03 2014-11-05 山东三星玉米产业科技有限公司 一种食用调和油及其制备方法
AU2014350157A1 (en) * 2013-11-15 2016-04-14 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
US10940158B2 (en) 2013-11-15 2021-03-09 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section
ES2916813T3 (es) * 2013-11-15 2022-07-06 Nestle Sa Composiciones para uso en la prevención o tratamiento de enterocolitis necrotizante en lactantes y niños pequeños
ES2689844T5 (es) 2013-12-13 2022-12-02 Nestle Sa Uso de una fórmula para bebés que contiene suero lácteo dulce, para promover el desarrollo neuronal postnatal del tubo digestivo de bebés, y el establecimiento de las funciones intestinales que controla
CN105899089A (zh) * 2013-12-19 2016-08-24 雀巢产品技术援助有限公司 用于减少婴儿代谢应激、降低肠道通透性和接近母乳喂养婴儿的生长速度的营养组合物
EP3288389A4 (en) * 2015-04-28 2018-10-10 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
AU2017307455B2 (en) * 2016-08-04 2023-07-06 Société des Produits Nestlé S.A. Nutritional compositions with 2FL and LNnT for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
EP3661371A1 (en) * 2017-08-04 2020-06-10 Société des Produits Nestlé S.A. Probiotic bacteria preconditioned in a gos-containing medium and use thereof
WO2019122178A1 (en) * 2017-12-21 2019-06-27 Societe Des Produits Nestle S.A. Compositions comprising at least on n-acetylated and at least one fucosylated oligosaccharide for use in the promotion of digestive capacity in infants and young children
AU2018387291B2 (en) * 2017-12-21 2024-10-10 Societe Des Produits Nestle S.A. Compositions for use in the promotion of intestinal muscle growth and development and associated intestinal motility
CN110038020A (zh) * 2019-04-23 2019-07-23 河南省农业科学院 唾液酸模拟物在制备抑制巨噬细胞感染或激活状态下所引起炎症的药物中的应用
CN110839698A (zh) * 2019-11-29 2020-02-28 内蒙古伊利实业集团股份有限公司 一种组合物及其食品用途
WO2022117709A2 (en) 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Composition for preterm infants to reduce time to full enteral feeding
EP4032536A1 (en) 2021-01-26 2022-07-27 Probisearch, S.L.U. Probiotic composition for infants and its uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895838A (en) 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
EP0481038B1 (en) 1990-04-16 2002-10-02 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
WO1999049882A2 (en) * 1998-03-27 1999-10-07 Eicher Dorothea J Vegf and vegf-c as infant formula supplements
CA2530437C (en) * 2003-06-23 2011-11-15 Nestec S.A. Nutritional formula for optimal gut barrier function
AU2004283626B2 (en) 2003-10-24 2010-07-15 N.V. Nutricia Synbiotic composition for infants
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
CN101415461A (zh) * 2006-01-09 2009-04-22 儿童医院医疗中心 用于治疗各种疾病的脂连蛋白
ES2342625T5 (es) 2006-02-10 2020-05-07 Nestle Sa Mezcla de oligosacáridos
RU2445362C2 (ru) * 2006-02-15 2012-03-20 Нестек С.А. Применение bifidobacterium longum в производстве лекарственного средства или терапевтической питательной композиции для лечения воспалительного заболевания кишечника у млекопитающего и для ослабления воспаления кишечника, связанного с пищевыми аллергенами, у млекопитающего
AU2007222598B2 (en) * 2006-03-07 2013-01-10 Société des Produits Nestlé S.A. Synbiotic mixture
RU2444911C2 (ru) * 2006-03-23 2012-03-20 Н.В. Нютрисиа Смесь для кормления недоношенных детей
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
RU2012107695A (ru) 2009-07-31 2013-09-10 Нестек С.А. Питательная композиция для вскармливаемых грудью детей или домашних животных с пробиотиками и подобранными питательными веществами
EP2308498A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Administration of Bifidobacterium breve during infancy to prevent inflammation later in life
EP2455387A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula

Also Published As

Publication number Publication date
CL2014000791A1 (es) 2014-08-22
ES2666491T3 (es) 2018-05-04
EP2768311B2 (en) 2025-05-28
US20140286908A1 (en) 2014-09-25
CN103889239A (zh) 2014-06-25
AU2012324985A1 (en) 2014-03-20
PH12014500509B1 (en) 2019-02-13
EP2768311A1 (en) 2014-08-27
WO2013057062A1 (en) 2013-04-25
PH12014500509A1 (en) 2014-04-14
MX390997B (es) 2025-03-21
EP2768311B1 (en) 2018-02-21
RU2624233C2 (ru) 2017-07-03
AU2012324985B2 (en) 2016-01-07
BR112014008425A2 (pt) 2017-04-11
ES2666491T5 (en) 2025-10-27
RU2014119904A (ru) 2015-11-27

Similar Documents

Publication Publication Date Title
MX2014004719A (es) Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal.
MX2013007674A (es) Productos nutricionales que incluyen monogliceridos y acidos grasos.
BR112014015940A8 (pt) composição de novo fármaco de carboidrato para tratamento de doenças humanas
PH12014500558A1 (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
PH12013501892A1 (en) Nutritional compositions including branched chain fatty acids for wound healing
BR112015011843A8 (pt) composição para promover a saúde intestinal
CR20130411A (es) Composiciones de puré que tienen proporciones de carbohidrato específicas y los métodos para utilizar las mismas
GB2491775A (en) Pulsatile drug release
MX2013010076A (es) Composiciones y metodos que comprenden c16:1n7 palmitoleato.
MX354661B (es) Aditivos para alimentación animal.
TR201910903T4 (tr) Osteoporoz hastalıkları profilaksisi için biyolojik olarak aktif gıda katkısı.
WO2013049519A3 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
MX2022001225A (es) Metodo para mejorar la salud digestiva.
MX2015015628A (es) Acido graso del aceite de bogol para uso en suplementos y composiciones de tratamiento y piensos para animales.
PH12015502679A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
CL2014001385A1 (es) Metodo y composicion para aumentar la proporcion de ingredientes dietarios que son resistentes a la degradacion por los microorganismos del rumen
PH12014500344A1 (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
MX2013010415A (es) Tratamiento de la atrofia vaginal con nueva indicacion para la mirra.
BR112013021376A2 (pt) composição para aumentar a estabilidade da articulação e/ou postural
PE20141022A1 (es) Composiciones y procedimientos para la administracion de nutrientes
IN2015DN00461A (es)
NZ613264A (en) Use of vitamin k for weight maintenance and weight control
GB2528406A (en) Prebiotic composition and method of its use
MX2012008317A (es) Uso prebiotico de polisacarido de soja soluble en agua.